⌘+K

Company description

Paxman, founded in the UK in 1996, is the market leader in scalp-cooling technology that helps reduce hair loss during chemotherapy. The company is also developing a device to prevent chemotherapy-induced peripheral neuropathy (CIPN) in the hands and feet, with clinical trials underway in Singapore and the US.

Key industry drivers

  • Growing global cancer incidence.

  • Rising focus on quality of life during treatment.

  • Expanding reimbursement frameworks.

Industry outlook

  • We see a stable outlook driven by rising cancer rates, robust chemotherapy volumes (especially in the US) and a growing focus on quality of life, supporting demand for supportive care solutions.

  • Key peers

    OssDsign, Surgical Science, Xvivo Perfusion.

    Shareholders

    Name

    Capital

    Votes

    Glenn Paxman

    10.9 %

    10.9 %

    Jesper Lyckeus

    6.5 %

    6.5 %

    Per-Anders Johansson

    5.6 %

    5.6 %

    Richard Paxman

    5.3 %

    5.3 %

    Eiffel Investment Group SAS

    5.1 %

    5.1 %

    Andra AP-fonden

    4.6 %

    4.6 %

    About DNB Carnegie Access

    DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.

    Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.

    Private Banking

    Tailored wealth management. Your financial future, personalized.

    Montrose

    A digital investment platform designed for passionate investors.

    DNB Carnegie

    Leading Nordic investment bank and wealth management.

    © Copyright DNB Carnegie Investment Bank AB